BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 28012224)

  • 1. Continuation of low-molecular-weight heparin treatment for cancer-related venous thromboembolism: a prospective cohort study in daily clinical practice.
    van der Wall SJ; Klok FA; den Exter PL; Barrios D; Morillo R; Cannegieter SC; Jimenez D; Huisman MV
    J Thromb Haemost; 2017 Jan; 15(1):74-79. PubMed ID: 28012224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of unfractionated heparin versus low-molecular-weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancer.
    Van Matre ET; Reynolds PM; MacLaren R; Mueller SW; Wright GC; Moss M; Burnham EL; Ho PM; Vandivier RW; Kiser TH
    J Thromb Haemost; 2018 Dec; 16(12):2492-2500. PubMed ID: 30347498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
    Robertson L; Strachan J
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD006771. PubMed ID: 28195640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery.
    Felder S; Rasmussen MS; King R; Sklow B; Kwaan M; Madoff R; Jensen C
    Cochrane Database Syst Rev; 2019 Aug; 8(8):CD004318. PubMed ID: 31449321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
    Andras A; Sala Tenna A; Stewart M
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD002001. PubMed ID: 28737834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
    Di Nisio M; Porreca E; Candeloro M; De Tursi M; Russi I; Rutjes AW
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD008500. PubMed ID: 27906452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unfractionated heparin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in trauma.
    Jacobs BN; Cain-Nielsen AH; Jakubus JL; Mikhail JN; Fath JJ; Regenbogen SE; Hemmila MR
    J Trauma Acute Care Surg; 2017 Jul; 83(1):151-158. PubMed ID: 28426561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
    Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Terrenato I; Sperati F; Barba M; Yosuico VE; Schünemann H; Akl EA
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006650. PubMed ID: 29920657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS Study.
    Napolitano M; Saccullo G; Malato A; Sprini D; Ageno W; Imberti D; Mascheroni D; Bucherini E; Gallucci P; D'Alessio A; Prantera T; Spadaro P; Rotondo S; Di Micco P; Oriana V; Urbano O; Recchia F; Ghirarduzzi A; Lo Coco L; Mancuso S; Casuccio A; Rini GB; Siragusa S
    J Clin Oncol; 2014 Nov; 32(32):3607-12. PubMed ID: 25267738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients.
    Carrier M; Le Gal G; Cho R; Tierney S; Rodger M; Lee AY
    J Thromb Haemost; 2009 May; 7(5):760-5. PubMed ID: 19245418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Patterns and Clinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: A Retrospective Cohort Study.
    Bang SM; Kang JH; Hong MH; Ahn JS; Oh SY; Baek JH; Choi YJ; Shin SH; Kim YJ; Gil HY; Park HE; Lee J; Park EL
    Clin Appl Thromb Hemost; 2021; 27():1076029620979575. PubMed ID: 33471574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of venous thromboembolism prophylaxis with fondaparinux or low molecular weight heparin in a large cohort of consecutive patients undergoing major orthopaedic surgery - findings from the ORTHO-TEP registry.
    Donath L; Lützner J; Werth S; Kuhlisch E; Hartmann A; Günther KP; Weiss N; Beyer-Westendorf J
    Br J Clin Pharmacol; 2012 Dec; 74(6):947-58. PubMed ID: 22515679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term therapy with low-molecular-weight heparin in cancer patients with venous thromboembolism.
    Marchena PJ; Nieto JA; Guil M; García-Bragado F; Rabuñal R; Boccalon H; Trujillo-Santos J; Monreal M;
    Thromb Haemost; 2012 Jan; 107(1):37-43. PubMed ID: 22116496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
    Andras A; Sala Tenna A; Crawford F
    Cochrane Database Syst Rev; 2012 Oct; 10():CD002001. PubMed ID: 23076894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery.
    Felder S; Rasmussen MS; King R; Sklow B; Kwaan M; Madoff R; Jensen C
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD004318. PubMed ID: 30916777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulation for people with cancer and central venous catheters.
    Kahale LA; Tsolakian IG; Hakoum MB; Matar CF; Barba M; Yosuico VE; Terrenato I; Sperati F; Schünemann H; Akl EA
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006468. PubMed ID: 29856471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison Between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism.
    Chen DY; Tseng CN; Hsieh MJ; Lan WC; Chuang CK; Pang ST; Chen SW; Chen TH; Chang SH; Hsieh IC; Chu PH; Wen MS; Chen JS; Chang JW; See LC; Huang WK
    JAMA Netw Open; 2021 Feb; 4(2):e2036304. PubMed ID: 33533929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.
    Akl EA; Kahale L; Barba M; Neumann I; Labedi N; Terrenato I; Sperati F; Muti P; Schünemann H
    Cochrane Database Syst Rev; 2014 Jul; (7):CD006650. PubMed ID: 25004410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
    Di Nisio M; Porreca E; Otten HM; Rutjes AW
    Cochrane Database Syst Rev; 2014 Aug; (8):CD008500. PubMed ID: 25171736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
    Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
    JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.